<DOC>
	<DOC>NCT02254655</DOC>
	<brief_summary>The purpose of this study is to access the effect (week 12/week 24) of puerarin injection on carotid intima-media thickness (CIMT) in rheumatoid arthritis (RA) patients despite routine anti-rheumatic treatment.</brief_summary>
	<brief_title>The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>- Controlled, randomized trial - RA patients under routine anti-rheumatic care were randomized to receive the treatment with or without 400 mg puerarin injection - Assessments were made at entry, 12 and 24 weeks - The overall sample size was assessed before the enrollment - Randomization was performed using concealed random allocation method - The collected data was processed and assessed by two reviewers - All the measurement and analysis procedures concerning CIMT were performed by a single ultra sonographer and a single reader, who were blinded to patient profiles and group assignment - The reproducibility of the ultrasonographic method was test before the trial</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Protective Agents</mesh_term>
	<mesh_term>Puerarin</mesh_term>
	<criteria>patients with a definite diagnose of rheumatoid arthritis(RA) were included if they met the classification criteria for RA established by the American Rheumatism Association (ACR) and European League Against Rheumatism (EULAR) in 2010 aged from 18 to 75 years without conflict to the written, informed consent signed prior to the enrollment no severe hepatic or renal disorders no known carotid artery stenosis no coagulation disorders no hypertension being in pregnancy, lactation period or under a pregnancy plan being allergic to the test drug not compatible for the trial medication without full legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>puerarin</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>carotid intima-media thickness</keyword>
</DOC>